Divergent Progress For Chinese Developers Of COVID Antivirals, Vaccines
Factors Include Demand, New Strains
Executive Summary
Some of China's makers of COVID-19 antivirals are fast-tracking neutralizing antibodies and peptide fusion inhibitors in clinical trials, while vaccine developers are embroiled in a tougher situation against the mutating coronavirus.
You may also be interested in...
Chinese Vaccine Developers' Latest COVID Shots Target XBB Subvariants
Chinese vaccine companies WestVac, Sinocelltech and Walvax/RNACure are leading domestic efforts to develop new shots targeting emerging SARS-CoV-2 subvariants.
China Grants First mRNA COVID Vaccine Approval To Homegrown Latecomer
CSPC Pharmaceutical's SYS6006 has gained an emergency use authorization in China less than one year after entering clinical trials, becoming the first mRNA vaccine for COVID-19 to be approved in the country.
Chinese Companies Progress Peptide Fusion Inhibitors For COVID-19
China's Hybio, Youcare and Shanxi Jinbo appear to be the only three companies in the world trying to develop a fusion inhibitor for COVID-19, the most advanced of which has now moved into a domestic Phase II trial.